Transcatheter Device Used to Treat Secondary Mitral Valve Regurgitation in Heart Failure Patients Reduces Hospitalizations, Enhances Quality of Life, and Improves Survival
Cardiovascular Research Foundation (CRF)Data presented today from the randomized COAPT trial, which have the potential to significantly change current clinical practice, found that patients with heart failure and secondary mitral regurgitation (MR) who remained symptomatic despite maximally tolerated medical therapy demonstrated reduced rates of hospitalizations and death, as well as improved quality-of-life and functional capacity after being treated with the transcatheter MitraClip device.